Amarantus Provides Update on Capital Restructuring and Announces Participation in RESI JPM 2018 http://bit.ly/2CJYTNh

Amarantus Subsidiary Cutanogen Corporation Announces Patent Issuance in Hong Kong Covering ESS, Pigmented ESS and Gene Therapy-Modified ESS http://bit.ly/2CoPJWf

Amarantus Subsidiary MANF Therapeutics Announces Patent Issuances in Europe and China Covering MANF as a Treatment and Biomarker in Diabetes and Publication of MANF Human Pre-Diabetes and Diabetes Biomarker Data http://bit.ly/2Cj6QJ2

Amarantus Subsidiary MANF Therapeutics Announces Retinal Patent Issuances in Europe Covering MANF & CDNF and Positive Data for MANF in Glaucoma http://bit.ly/2BEeBJ8

Amarantus Subsidiary MANF Therapeutics Announces Issuance of Japanese Patent Covering Therapeutic Use of MANF in Treatment of Parkinson's Disease http://bit.ly/2B7oyhT

Amarantus Subsidiary MANF Therapeutics Announces Publication in Science Magazine of Positive Animal Data for MANF in Treatment of Retinal Damage and Issuance of Retinal Patent in Japan Covering MANF and CDNF

Amarantus Provides Comprehensive Corporate Update

Amarantus Enters Into Forbearance and Capital Restructuring Agreements With Holders of Secured Debt, Convertible Preferred Stock and Warrants http://bit.ly/2zIWGTU

Amarantus today announced the publication of a 16-subject clinical study of Engineered Skin Substitute ("ESS," or "Permaderm™") in children with life-threatening severe burns. In this study, ESS was compared with the standard of care (split-thickness autograft "AG") for treating full-thickness (dermal and epidermal layers of skin) life-threatening pediatric severe burns covering a total body surface area (TBSA) of 50% or greater. The article entitled "Randomized, Paired-Site Comparison of Autologous Engineered Skin Substitutes and Split-Thickness Skin Graft for Closure of Extensive, Full-Thickness Burns" was published online in the July edition of the Journal of Burn Care and Research (Boyce, et al, 2016). For a summary of the data and a link to the publication, click here: http://bit.ly/2aUoDup

Amarantus BioScience Holdings, Inc. today announced that the current Good Manufacturing Practices (cGMP) manufacturing process for its Engineered Skin Substitute (ESS) program is now qualified at Lonza Walkersville, Inc., a premier contract manufacturer providing cell and tissue-based products for clinical development. Reaching this milestone signifies that Amarantus is now positioned to supply ESS for its planned opening of the 10-patient, randomized, placebo-controlled, open-label Phase 2 clinical trial for the treatment of adult patients (ages 18-40 years old) with deep-partial and full-thickness thermal burns covering ≥50% of total body surface area (TBSA). The Company will open enrollment at the first site, the U.S. Army’s Institute for Surgical Research (ISR) at Fort Sam Houston in Texas, under a Collaborative Research & Development Agreement (CRADA). Two additional civilian sites will be opened after ISR to accelerate enrollment of the study. For additional study information, read the full press release available here: http://bit.ly/1UnzIRk